Title

Nab-paclitaxel-based therapy in underserved patient populations: The abound.Ps2 study in patients with nsclc and a performance status of 2.

Document Type

Article

Publication Date

1-1-2018

Publication Title

Front Oncol

Abstract

Introduction: The phase II ABOUND.PS2 study (NCT02289456) assessed safety/tolerability of a first-line modified

Methods: Chemotherapy-naive patients with stage IIIB/IV NSCLC and ECOG PS 2 received four cycles of

Results: 11/40 treated patients (27.5%; 95% CI, 14.60-43.89) discontinued chemotherapy induction due to TEAEs; 16/40 (40.0%) continued

Conclusion: This

PubMed ID

30087850

Volume

8

First Page

253

Share

COinS